Allison Bratzel
Stock Analyst at Piper Sandler
(1.97)
# 1188
Out of 5,358 analysts
40
Total ratings
56.67%
Success rate
24.20%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REPL Replimune Group | Maintains: Overweight | 14 22 | 10.39 | 111.74% | 2 | Jun 2, 2025 | |
TYRA Tyra Biosciences | Assumes: Overweight | 33 | 10.58 | 211.91% | 1 | May 21, 2025 | |
RARE Ultragenyx Pharmaceu... | Maintains: Overweight | 140 115 | 37.17 | 209.39% | 1 | Mar 17, 2025 | |
AKBA Akebia Therapeutics | Maintains: Overweight | 4 6 | 3.96 | 51.52% | 1 | Mar 14, 2025 | |
INZY Inozyme Pharma | Maintains: Overweight | 30 23 | 3.99 | 476.44% | 1 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 26 | 3.75 | 593.33% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 620 725 | 585.97 | 23.73% | 13 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 12 22 | 15.31 | 43.7% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 23 | 21.51 | 6.93% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 62 | 35.3 | 75.64% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 42 | 34.26 | 22.59% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 22 | 11.22 | 96.08% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 4 | 2.59 | 54.44% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 8 20 | 4.54 | 340.53% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 20 | 2.45 | 716.33% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 23 25 | n/a | n/a | 1 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 | 68.77 | 45.41% | 2 | Feb 8, 2023 |